FORA Capital’s Enliven Therapeutics ELVN Stock Holding History

FORA Capital’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,723	Closed	-$577K	–	423
2026 Q1	$577K	Buy	+14,723	New	+$408K	0.04%	294

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

FORA Capital's ELVN Position: Q2 2026 in Review

FORA Capital sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 14,723 shares — an estimated $577K sold.

FORA Capital first reported a position in ELVN in Q1 2026 and held it in 1 quarter. The position peaked at $577K in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

FORA Capital reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
FORA Capital sold 14,723 Enliven Therapeutics shares in Q2 2026, an estimated $577K.
FORA Capital first reported a position in Enliven Therapeutics in Q1 2026 and held it in 1 quarter.
FORA Capital's Enliven Therapeutics position peaked at $577K in Q1 2026.
213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.